Effect of Escherichia coli and Lactobacillus casei on Luteolin Found in Simulated Human Digestion System

Seung-Jae Lee¹, Seung Yuan Lee¹ and Sun Jin Hur^1,

¹Department of Animal Science and Technology, Chung-Ang University, 4726 Seodong-daero, Daedeok-myeon, Anseong-si, Gyeonggi 450-756, Republic of Korea

Cite this paper:
Seung-Jae Lee, Seung Yuan Lee and Sun Jin Hur. Effect of Escherichia coli and Lactobacillus casei on Luteolin Found in Simulated Human Digestion System. Journal of Food and Nutrition Research. 2015; 3(5):311-316. doi: 10.12691/jfnr-3-5-4

Abstract

This study was conducted to investigate the effects of in vitro human digestion and enterobacteria (Escherichia coli and Lactobacillus casei) on the digestibility and structure of luteolin. Luteolin was passed through an in vitro digestion system that simulates the composition of the human mouth, stomach, small intestine, and large intestine and contains enterobacteria. The luteolin content was not altered by mouth or stomach digestion, but it was decreased by small intestine digestion. Large intestine digestion by enterobacteria also decreased the luteolin content; L. casei reduced the luteolin content more than E. coli. Moreover, digestion in the large intestine by a combination of E. coli and L. casei reduced the luteolin content more than digestion by individual enterobacteria. This study will provide insight into how enterobacteria influence the digestibility and structure of phytochemicals.

Keywords:
In vitro human digestion luteolin enterobacteria escherichia coli lactobacillus casei

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Boisen, S., & Eggum, B. O. (1991). Critical evaluation of in vitro methods for estimating digestibility in simple-stomach animals. Nutrition Research Reviews, 4(1), 141-162.
[2]	Boyer, J., Brown, D., & Liu, R. H. (2005). In vitro digestion and lactase treatment influence uptake of quercetin and quercetin glucoside by the Caco-2 cell monolayer. Nutrition Journal, 4, 1.
[3]	Braune, A., Gutschow, M., Engst, W., Blaut, M. (2001). Degradation of quercetin and luteolin by Eubacterium ramulus. Applied and Environmental Microbiology. 5558-5567.
[4]	Coles, L. T., Moughan, P. J., & Darragh, A. J. (2005). In vitro digestion and fermentation methods, including gas production techniques, as applied to nutritive evaluation of foods in the hindgut of humans and other simple-stomached animals. Animal Feed Science and Technology, 123–124, Part 1, 421-444.
[5]	Fuller, F. (1991). In Vitro Digestion for Pigs and Poultry: C.A.B. International.
[6]	Hur, S. J., Decker, E. A., & McClements, J. D. (2009). Influence of initial emulsifier type on microstructural changes occurring in emulsified lipids during in vitro digestion. Food Chemistry, 114, 253-262.
[7]	Hur, S. J., Lim, B. O., Decker, E. A., & McClements, D. J. (2011). In vitro human digestion models for food applications. Food Chemistry, 125(1), 1-12.
[8]	Hur, S. J., Lee, S. Y., Kim, Y. C., Choi, I., Kim, G. B. 2014. Effect of fermentation on the antioxidant activity in plant-based foods. Food Chemistry. 160: 346-356.
[9]	Lee, L. T., Huang, Y. T., Hwang, J. J., Lee, P., Ke, F. C., Nair, M. P., Kanadaswam, C., & Lee, M. T. (2001). Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer research, 22(3), 1615-1627.
[10]	Liao, P. H., Hung, L. M., Chen, Y. H., Kuan, Y. H., Zhang, F. B. Y., Lin, R. H., Shih, H. C., Tsai, S. K., & Huang, S. S. (2011). Cardioprotective Effects of Luteolin During Ischemia-Reperfusion Injury in Rats. Circulation Journal, 75(2), 443-450.
[11]	Mencherini, T., Picerno, P., Scesa, C., & Aquino, R. (2007). Triterpene, Antioxidant, and Antimicrobial Compounds from Melissa officinalis. Journal of Natural Products, 70(12), 1889-1894.
[12]	Ong, C.-S., Zhou, J., Ong, C. N., & Shen, H. M. (2010). Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt–GSK-3β–Cyclin D1 pathway. Cancer Letters, 298(2), 167-175.
[13]	Reid, G., McGroarty, J. A., Angotti, R., Cook, R. L. 1988. Lactobacillus inhibitor production against Escherichia coli and coaggregation ability with uropathogens. Canadian Journal of Microbiology. 34(3): 344-351.
[14]	Seelinger, G., Merfort, I., & Schempp, C. M. (2008). Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta medica, 74(14), 1667-1677.
[15]	Shimoi, K., Okada, H., Furugori, M., Goda, T., Takase, S., Suzuki, M., Hara, Y., Yamamoto, H., & Kinae, N. (1998). Intestinal absorption of luteolin and luteolin 7-O-β-glucoside in rats and humans. FEBS Letters, 438(3), 220-224.
[16]	Versantvoort, C. H. M., Oomen, A. G., Van de Kamp, E., Rompelberg, C. J. M., & Sips, A. J. A. M. (2005). Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food. Food and Chemical Toxicology, 43(1), 31-40.
[17]	Walter, J. (2008). Ecological role of lactobacilli in the gastrointestinal tract: Implications for fundamental and biomedical research. Applied and Environmental Microbiology, 74(16), 4985-4996.
[18]	Xagorari, A., Papapetropoulos, A., Mauromatis, A., Economou, M., Fotsis, T., & Roussos, C. (2001). Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. Journal of Pharmacology and Experimental Therapeutics, 296(1), 181-187.